Theragen Genomecare, which is a subsidiary of Theragen Etex, announced to export NIPT (Non-Invasive Prenatal Test) technology in UAE and Middle East.
Theragen Genomecare is the first NIPT service company in Kroea to have published four papers  in the SCI class journal (PLOS ONE. October 2014 / BMC Medical Genomics. April 2016)
This time, UAE export is not just a service supply contract but a technology export. The existing supply contract was a form of analyzing blood and sending the results to Korea from a foreign country, which led to the weakness of being highly time-consuming and costly and suitable for small services. However, since the contract is designed to transfer experimental and analytical technologies directly to the UAE and handle them with one stop, it will reduce the time and cost. It is expected that it will take about 3 to 4 months before entire technology is transferred and that sales will start from May to June this year.
Jeong Myung-joon, CEO of Jinum Care, said, The technology transfer process is accelerating as the $ 25,000 contract was already deposited to Jinome Care on January 11, 2018. In addition, the sales and royalties of analysis programs are expected to generate more than 200,000 USD per year over the next five years.
Zenoma is a non-invasive, safe child test service that uses a non-vitro method of separating the DNA of the fetus from the blood of the pregnant woman without taking positive or placenta. The benefits of a mother's mother's blood collection are safe and convenient tests, early diagnosis from the 10th week of pregnancy, accuracy of 99 percent, binatal examination, and quick verification within seven business days.